SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-028603
Filing Date
2023-08-14
Accepted
2023-08-14 17:00:57
Documents
66
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1653077
2 ex31-1.htm EX-31.1 18844
3 ex31-2.htm EX-31.2 18857
4 ex32-1.htm EX-32.1 7560
5 ex32-2.htm EX-32.2 7330
  Complete submission text file 0001493152-23-028603.txt   8621618

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mymd-20230630.xsd EX-101.SCH 50808
7 XBRL CALCULATION FILE mymd-20230630_cal.xml EX-101.CAL 50716
8 XBRL DEFINITION FILE mymd-20230630_def.xml EX-101.DEF 283979
9 XBRL LABEL FILE mymd-20230630_lab.xml EX-101.LAB 468749
10 XBRL PRESENTATION FILE mymd-20230630_pre.xml EX-101.PRE 379408
60 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1652731
Mailing Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 231171736
SIC: 2835 In Vitro & In Vivo Diagnostic Substances